A28 Therapeutics is developing a targeted lytic peptide platform, specifically the AT-101 compound, which binds to LHRH receptors overexpressed on various cancer cells to induce cell death while minimizing damage to healthy tissue. This approach addresses the need for more effective and less toxic cancer treatments across multiple solid tumors and hematological malignancies.

BIOMx develops customized bacteriophage therapies to target and eliminate harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. By validating proprietary bacterial targets, the company creates tailored phage compositions that enhance treatment efficacy and patient outcomes.

The startup develops small molecules to treat sensory hyperexcitability disorders by targeting both a ligand-gated cation channel and a voltage-gated potassium channel. This dual-target approach enhances therapeutic efficacy and safety for patients experiencing heightened sensory responses.

Catch offers a rewards debit card that allows users to earn cash back on purchases made directly from their bank accounts, eliminating credit card fees and debt. The platform provides automatic store credit at partner brands, enhancing customer loyalty while enabling users to save on everyday expenses.

Circuit-Bio develops a synthetic gene circuit platform that produces a combination of immune-stimulating proteins specifically in targeted tumor cells, addressing the challenges of poor efficacy and off-target activity in cancer immunotherapy. This technology transforms cancer cells into agents that elicit a robust anti-tumoral immune response, tailored to individual patient needs.

The startup develops cell and gene therapy technologies that utilize biological vehicles for delivering therapeutic proteins directly into the central nervous system. This approach targets neurodevelopmental and neurological disorders, such as Rett syndrome, by enabling direct neuron protein replacement treatments for more effective disease management.

ImmPACT Bio USA is developing logic-gated CAR T cell therapies that prevent antigen escape and rewire T cell responses to overcome the immunosuppressive tumor microenvironment in cancer. Their technology aims to enhance the specificity of T cell targeting, enabling effective treatment of solid tumors while sparing normal tissue.

Osmol Therapeutics is developing OSM-0205, an intravenous treatment designed to prevent chemotherapy-induced peripheral neuropathy (CIPN) and cognitive impairment (CICI) by targeting calcium surge interactions that lead to neuronal damage. This approach aims to enhance chemotherapy dosing and improve patient outcomes for those at risk of debilitating side effects from taxane-based therapies.

RA UNLIMITED harnesses solar photovoltaic technology to generate clean and affordable electricity for homes, businesses, and communities in the Philippines. The company addresses the reliance on fossil fuels by providing sustainable energy solutions that create jobs and enhance the quality of life for Filipinos.

Renable offers an AI-powered platform and track & trace technology to optimize material recirculation for a circular economy. The system provides transparent and documentable processes for dismantling and recycling industrial materials, starting with the maritime sector, to deliver certified circular materials and reduce emissions.

SeraGene Therapeutics develops RNA-based therapies that utilize liver-targeting drug delivery systems to restore hemostasis by modulating clotting protein expression in patients with coagulation disorders. The company focuses on providing long-lasting treatment options for rare bleeding disorders, thrombotic conditions, and enhancing transfusable platelets, thereby improving the quality of life for affected individuals.

SKIP Therapeutics develops RNA-based therapies, specifically Antisense Oligonucleotides (ASOs), to address rare genetic disorders and common diseases. The company utilizes a proprietary computational discovery engine to optimize target selection and therapeutic design for modulating gene function. This platform integrates genomic and proteomic data to efficiently identify and evaluate ASO strategies for splicing modulation and gene expression control.